Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CDA Activity in MDS and AML Patients Treated with Azacytidine
NCT02489929Unknown
- Sponsor
- Assistance Publique-Hôpitaux de Marseille
- Start
- Aug 2015
- Primary completion
- Aug 2018
- Countries
- 1
01
Overview
Open-label trial of azacitidine in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), sponsored by Assistance Publique-Hôpitaux de Marseille. Primary endpoint: Progression-Free Survival at 3 years. Status: unknown.
02
Drugs
azacitidine
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02489929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02489929.